Rigel Pharmaceuticals
- Market cap
- 896.45M
- P/E (TTM)i
- 2.84
- P/Bi
- 2.11
- EPSi
- 19.48
- Div yieldi
- 0.00%
- 52W posi
- 84%
Anonymous reader poll. Unscientific, not investment advice.
About Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
- Founded
- 1996
- CEO
- Mr. Raul R. Rodriguez
- Employees
- 174
- Headquarters
- South San Francisco, California, United States of America
- Fiscal year end
- 12-31
- Website
- rigel.com
Company profile
- Exchange
- US
- Symbol
- RIGL
- Market-cap rank
- #3318
- Market cap
- 896.45M
- Float cap
- 712.17M
- Shares out
- 18.68M
- Float shares
- 14.84M
Sectors & themes
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.